PLX today
$2.96-$0.17 (-5.59%)close Nov 12, 2026Trend
DailyDowntrend (starting)
4 hourLeaning Bullish
1 hourStrong Bearish
15 minBearish
5 minStrong Bearish
Daily trend turns up above $2.85
Key levels
Resistance$3.19
Resistance$3.02
Support$2.85
Support$2.68
Latest news & SEC filings
EarningsProtalix BioTherapeutics Posts Q3 2026 Financials
AnalystGoldman Sachs raises Pluxee rating to Neutral
LegalJudge in Brazil halts new PAT food program changes
EarningsProtalix BioTherapeutics holds Q3 2026 earnings call
SEC FilingProtalix BioTherapeutics, Inc. filed a report on a major company event (Form 8-K)
All PLX news →About Protalix BioTherapeutics
Protalix BioTherapeutics is a commercial-stage biopharmaceutical company that develops and manufactures treatments for rare diseases using its plant cell-based protein expression platform, ProCellEx. Its two approved enzyme replacement therapies are Elelyso for Gaucher disease and Elfabrio for Fabry disease. Elelyso is licensed to Pfizer for most markets and to Fiocruz in Brazil, while Elfabrio is partnered with Chiesi for global commercialization. The company also develops earlier-stage candidates, including PRX-115 for uncontrolled gout and PRX-119 for NETs-related diseases.
Based on the company's 10-K filed Mar 18, 2026.
NYSE · Healthcare
Protalix BioTherapeutics, Inc. (PLX)
What Is the Price Target for PLX?
SEPT Low Target
$12.00
SEPT Mid Target
$12.00
SEPT High Target
$12.00
Analyst Consensus
$12.00
Is PLX a Buy or Sell Right Now?
Thesis
- •Revenue growing -1.2% YoY with STABLE trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for PLX.
Start Free Trial →Is PLX Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/E Forward, P/B, Analyst Consensus
Fair Value
$9.07
40
Moat Score
NARROW
2/9
Piotroski Score
-2.0
Altman Z-Score
What Is Smart Money Doing with PLX?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →PLX Growth Story
Revenue YoY
-1.2%
3yr Revenue CAGR
3.5%
EPS Growth YoY
-300%
FCF Growth YoY
-284.4%
Revenue Trend
STABLE
Dark Pool Trades for PLX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for PLX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:05 | $2.96 | 3,686 | $$11K | BUY |
| 20:59:40 | $2.96 | 2,648 | $$8K | BUY |
| 20:59:30 | $2.95 | 2,000 | $$6K | SELL |
| 20:58:31 | $2.96 | 3,800 | $$11K | BUY |
| 20:58:00 | $2.96 | 1,098 | $$3K | MIDPOINT |
5 dark pool trades shown · $$39K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Protalix BioTherapeutics, Inc. (PLX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →PLX — frequently asked questions
What is PLX stock price today?
Protalix BioTherapeutics, Inc. (PLX) is at $2.96, down 5.59% (-$0.17) at the Nov 12, 2026 close.
Why is PLX stock moving today?
Latest PLX news — Nov 11, 2026: Protalix BioTherapeutics Posts Q3 2026 Financials · Nov 10, 2026: Goldman Sachs raises Pluxee rating to Neutral
What is the PLX price target?
The average analyst price target for PLX is $12.00, ranging from $12 to $12, based on 1 analysts.
What do analysts rate PLX?
Analyst ratings for PLX: 0 Buy, 1 Hold, 0 Sell — consensus Hold.
Did PLX beat earnings?
PLX last reported on Aug 12, 2026: EPS $0.05 vs -$0.01 expected — a beat of 600.0%.
What is PLX's P/E ratio?
PLX trades at a P/E of 10.7 vs a Healthcare average of 17.1.
Does PLX pay a dividend?
PLX does not currently pay a dividend.
What are PLX support and resistance levels?
Support: $2.85, $2.68, $2.52. Resistance: $3.02, $3.19, $3.55.
What are insiders doing with PLX?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on PLX?
Nov 11, 2026: Protalix BioTherapeutics Posts Q3 2026 Financials · Nov 10, 2026: Goldman Sachs raises Pluxee rating to Neutral · Nov 10, 2026: Judge in Brazil halts new PAT food program changes